PT  - JOURNAL ARTICLE
AU  - Alexander, Lori
ED  - Yusuf, Salim
TI  - Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial
DP  - 2008 Jun 01
TA  - MD Conference Express
PG  - 12--13
VI  - 8
IP  - 2
4099  - http://mdc.sagepub.com/content/8/2/12.short
4100  - http://mdc.sagepub.com/content/8/2/12.full
AB  - The angiotensin-receptor blocker telmisartan is equally effective in reducing cardiovascular risk as the angiotensin-converting enzyme inhibitor ramipril in patients with vascular disease or high-risk diabetes. However, the combination is no more effective than either drug alone and causes more side effects according to results from the ONTARGET Trial.